Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

201 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Polymorphism of IL-1 receptor antagonist gene: role in cancer.
Sehouli J, Mustea A, Könsgen D, Katsares I, Lichtenegger W. Sehouli J, et al. Anticancer Res. 2002 Nov-Dec;22(6A):3421-4. Anticancer Res. 2002. PMID: 12530098 Review.
Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO). Oskay-Oezcelik G, et al. Anticancer Res. 2008 Mar-Apr;28(2B):1329-34. Anticancer Res. 2008. PMID: 18505074 Clinical Trial.
Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.
Pietzner K, Richter R, Chekerov R, Erol E, Oskay-Özcelik G, Lichtenegger W, Sehouli J. Pietzner K, et al. Anticancer Res. 2011 Aug;31(8):2679-82. Anticancer Res. 2011. PMID: 21778323
The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer.
Landt S, Heidecke H, Reuter C, Korlach S, Blohmer JU, Lichtenegger W, Heusner T, Stöblen F, Thill M, Barinoff J, Sehouli J, Kümmel S. Landt S, et al. Anticancer Res. 2011 Aug;31(8):2645-9. Anticancer Res. 2011. PMID: 21778317
Prognostic significance of angiogenic factors in uterine cervical cancer.
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kümmel S. Landt S, et al. Anticancer Res. 2011 Aug;31(8):2589-95. Anticancer Res. 2011. PMID: 21778309
Expression and localization of e-cadherin in epithelial ovarian cancer.
Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J. Koensgen D, et al. Anticancer Res. 2010 Jul;30(7):2525-30. Anticancer Res. 2010. PMID: 20682978
Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment.
Rack B, Schindlbeck C, Jückstock J, Genss EM, Hepp P, Lorenz R, Tesch H, Schneeweiss A, Beckmann MW, Lichtenegger W, Sommer H, Friese K, Janni W; SUCCESS Study Group. Rack B, et al. Anticancer Res. 2010 May;30(5):1837-41. Anticancer Res. 2010. PMID: 20592389 Clinical Trial.
Clinical management of borderline tumours of the ovary - experience from the "Berlin online tumour conference for gynaecological malignancies".
Sehouli J, Oskay-Oezcelik G, Pietzner K, Chen F, Coumbos A, Darb-Esfahani S, Schuback B, Heinrich G, Kronenberger C, Lorsbach M, Lichtenegger W, Chekerov R. Sehouli J, et al. Anticancer Res. 2010 May;30(5):1701-6. Anticancer Res. 2010. PMID: 20592364
Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer.
Landt S, Jeschke S, Koeninger A, Thomas A, Heusner T, Korlach S, Ulm K, Schmidt P, Blohmer JU, Lichtenegger W, Sehouli J, Kuemmel S. Landt S, et al. Anticancer Res. 2010 Feb;30(2):375-81. Anticancer Res. 2010. PMID: 20332442
201 results
Jump to page
Feedback